Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – Multiple Bristol-Myers Squibb Oncology Compounds to be Featured in Oral Presentations at 56th Annual American Society for Hematology (ASH) Meeting

[Business Wire] – Bristol-Myers Squibb Company today announced that study results on investigational agents Opdivo , a PD-1 immune checkpoint inhibitor, elotuzumab, an antibody targeted against Signaling Lymphocyte Activation Molecule , ulocuplumab, an . . . → Read More: Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – Multiple Bristol-Myers Squibb Oncology Compounds to be Featured in Oral Presentations at 56th Annual American Society for Hematology (ASH) Meeting Similar Articles: Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb to Present at Credit Suisse 2014 Health Care Conference Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Signs Exclusive Option Agreement to Acquire Galecto Biotech AB and Its Novel Galectin-3 Inhibitor in Development for Idiopathic Pulmonary Fibrosis Stock Update (NYSE:BMY): Bristol-Myers Squibb Announces Dividend